Knight Therapeutics Inc. (TSE:GUD - Get Free Report) dropped 0.2% on Monday . The company traded as low as C$5.75 and last traded at C$5.75. Approximately 14,003 shares traded hands during trading, a decline of 78% from the average daily volume of 63,092 shares. The stock had previously closed at C$5.76.
Analyst Upgrades and Downgrades
GUD has been the topic of a number of recent research reports. Research Capitl upgraded Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 11th. Stifel Nicolaus boosted their price target on Knight Therapeutics from C$6.25 to C$7.45 and gave the company a "buy" rating in a report on Tuesday, March 25th. Finally, Canaccord Genuity Group set a C$6.50 price objective on shares of Knight Therapeutics and gave the stock a "buy" rating in a research note on Friday, May 9th. Two analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Strong Buy" and an average price target of C$7.15.
Check Out Our Latest Report on GUD
Knight Therapeutics Trading Up 0.3%
The stock has a market cap of C$588.69 million, a PE ratio of -19.43, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The company has a 50 day moving average of C$5.84 and a two-hundred day moving average of C$5.64.
Insider Activity
In other news, insider Sime Armoyan sold 92,200 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of C$6.15, for a total value of C$567,030.00. Insiders have sold 3,143,300 shares of company stock worth $19,733,740 in the last quarter. Corporate insiders own 45.62% of the company's stock.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Read More
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
